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Abstract
Background: In the first and only literature review, conducted in 2009, of human insulin analog- induced
lipoatrophy, there were 12 published cases, including 1 with aspart, 1 with detemir, 1 with NovoMix 30 and none
with detemir plus aspart. It is perceived that insulin analog induced-lipoatrophy is increasing. We conducted a 2015
literature review of published reports of lipoatrophy induced by aspart, detemir, detemir plus aspart, and
NovoMix30. We also report a new case of detemir plus aspart and glulisine induced lipoatrophy.
Methods: Our focused literature searches (limited to 1995–2014) in PubMed, Embase, and Web of Science, using a
combination of insulin analog and lipoatrophy terminology, was conducted in early January 2015.
Results: From the 520 unique citations there were 33 (from 13 papers and 9 abstracts) lipoatrophy cases induced
by detemir (n = 5), aspart (n = 21), detemir plus aspart (n = 4) and NovoMix 30 (n = 3), representing 30 new cases
since 2009. Many of these reported cases were females (76 %), had type 1 diabetes mellitus (T1DM) (94 %) and
were in young persons (61 %). A 41-year-old T1DM woman developed lipoatrophy on her upper thighs, arms and
abdomen 14 months after injecting detemir plus aspart at the same sites. Later on, after a year on continuous
subcutaneous insulin infusion (CSII) using aspart and then glulisine, she developed lipoatrophy at the infusion sites.
When CSII insulin was switched to lispro she did not develop lipoatrophy after 10 months. Meanwhile, the original
lipoatrophy sites significantly improved.
Conclusions: Our literature review uncovered 30 new published cases of aspart, detemir, aspart plus detemir and
NovoMix 30-induced lipoatrophy since 2009. The largest increase in cases was in aspart- induced lipoatrophy.
Recent surveys showed most rapid acting insulin analog-induced lipoatrophy were associated with CSII. In our
review of the reported cases, 85.7 % cases of aspart-induced lipoatrophy were associated with CSII. As in previous
reports, we showed lipoatrophy was more common in females, T1DM and young persons. Our patient may be the
5th published case of detemir plus aspart-induced lipoatrophy and possibly the first case report of glulisine induced
lipoatrophy. She believed both detemir plus aspart and glulisine induced the lipoatrophy.
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Background
Insulin-induced lipoatrophy was a very common cutane-
ous complication of insulin therapy, found in 25- 55 %
of patients injecting bovine and porcine insulin [1]. It
became less common (<10 %) with purer animal and
human insulin [1]; and uncommon (about 1 %) after
human insulin analogs became available [2]. Lipoatrophy
has been reported in patients using basal (glargine [3]
and detemir [4]), rapid-acting (lispro [5], aspart [6] and
glulisine [7]) and mixture [8] insulin analogs injections.
In the first and only literature review of human insulin
analog-induced lipoatrophy, done in November 2009 [9],
there were 12 cases, including 1 with aspart, 1 with dete-
mir, 1 with NovoMix 30 (Biphasic aspart – 30 % aspart
70 %, NPH insulin) and none with detemir plus aspart.
Insulin analog induced lipoatrophy is perceived to be
increasing in prevalence [2]. In this paper we report a
literature review conducted in early January 2015 of
published reports of lipoatrophy induced by aspart, dete-
mir, detemir plus aspart, and NovoMix30 injections and
report a new case of lipoatrophy induced by detemir
plus aspart as well as glulisine injection. We will not
cover lipoatrophy induced by lispro, lispro mixtures, and
glargine in detail.
Methods
We conducted focused literature searches in early January
2015 in PubMed, Embase, and Web of Science using a
combination of insulin analog and lipoatrophy termin-
ology. We used MeSH and EMTREE controlled terms
when appropriate for broad concepts, such as “insulin
analog” [mesh] and lipodystrophy [mesh:noexp]. We sup-
plemented each controlled term with a comparable set of
title/abstract keywords, going so far as to include all indi-
vidual insulin analogs (‘lispro’, ‘humalog’, ‘aspart’, ‘novo-
log’, ‘detemir’, ‘levemir’, ‘glulisine’, ‘apidra’, and ‘glargine’,
‘lantus’). We also conducted a similar search in Web of
Science to primarily identify conference abstracts that
were not found in PubMed or Embase. We limited all
searches to articles and abstracts published between 1995
(when the first insulin analog was launched) and 2014,
and deliberately designed the searches to miss, when pos-
sible, citations pertaining to HIV-related lipoatrophy. We
exported citations into Endnote X6 (Thomson Reuters)
and used its functionality to eliminate duplicates.
We report a new case of a female type 1 diabetes mel-
litus (T1DM) patient who developed lipoatrophy when
injecting detemir plus aspart in the same site. Later on,
when using continuous subcutaneous insulin infusion
(CSII) to deliver aspart and then glulisine, she also de-
veloped lipoatrophy at the infusion sites. We obtained
written informed consent from the patient for publica-
tion of this case report and the images.
We requested information on lipoatrophy associated
with aspart and/or detemir injections from the manufac-
turer of these insulin analogs.
Results
Literature search
The literature search of PubMed, EMBASE and Web of
Science yielded 273, 252 and 119 citations respectively,
giving a combined total of 644 citations (Fig. 1). After
the duplicates were eliminated, we had 520 unique cita-
tions. Two authors (MT and NE) reviewed each of the
520 citations and concurred on those identified as lipoa-
trophy induced by insulin analog aspart, detemir, dete-
mir plus aspart and NovoMix 30 injections. We found
33 reported cases from 18 citations (13 papers/letters/
observations/vignette and 9 abstracts). From the refer-
ences of 13 papers, pearling was done to determine
whether they included other published abstracts/papers
on lipoatrophy induced by aspart, detemir, detemir plus
aspart, NovoMix 30 and glulisine injections. We found
none.
The 33 lipoatrophy cases are induced by detemir (n = 5)
[4, 10, 11], aspart (n = 21) [6, 10, 12–22], detemir plus
aspart (n = 4) [11, 23, 24], and NovoMix 30 (n = 3) [8, 10]
injections (Table 1). One of the detemir cases [4], one of
the aspart cases [6] and one of the NovoMix30 cases [8]
were previously described in the 2009 literature review [9],
giving 30 new cases since then: 4 detemir cases [10, 11], 20
aspart cases [10, 12–22], 2 NovoMix 30 [10], and 4 dete-
mir plus aspart cases [11, 23, 24]. The characteristics of
the 33 cases are:
Gender
Of the 5 patients with detemir-induced lipoatrophy, the
gender of 4 was stated. All were females. Of the 21 pa-
tients with aspart-induced lipoatrophy, the gender of 20
was stated. Of these, 13 were females and 7 were males.
All 4 patients with detemir plus aspart-induced lipoatro-
phy were females. Of the 3 patients with NovoMix 30-
induced lipoatrophy, 1 was female and the gender of the
other 2 was not stated.
Type of diabetes
All 5 patients with detemir-induced lipoatrophy had
T1DM. Twenty of the 21 patients with aspart-induced
lipoatrophy had T1DM and one had type 2 diabetes mel-
litus (T2DM). Among the 4 adult female patients with
detemir plus aspart-induced lipoatrophy, 2 had T1DM
and 2 had T2DM. All 3 patients with NovoMix 30-
induced lipoatrophy had T1DM.
Age
Four of the 5 patients with detemir-induced lipoatrophy
were adults and 1 was an adolescent. Fourteen of the 21
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patients with aspart-induced lipoatrophy were children,
3 were adults, 3 adolescents and 1 had no age men-
tioned. All 4 patients with detemir plus aspart- induced
lipoatrophy were adults. Two patients with Novo-Mix
30-induced lipoatrophy were children and 1 an adult.
Case
We report a 41-year-old Caucasian woman with T1DM
diagnosed in April 2010 who developed lipoatrophy on
her upper thighs, arms and abdomen injection sites in
June 2011 after being on multiple daily insulin regimen
of detemir plus aspart for 14 months (Fig. 2). Her
Hemoglobin A1c improved from 10.9 % at diagnosis to
6.4-7.4 % after starting these insulin analogs. She injected
both insulin analogs in the same sites and could not spe-
cify which insulin analog was the cause of these indenta-
tions. In September 2011 she started CSII using Omnipod
with aspart. New lipoatrophy developed at the infusion
sites within a year. In November 2012 glulisine was used
instead of aspart. When the infusion was above or below
the lipoatrophy thigh sites, the lipoatrophy worsened.
Therefore, she switched to abdominal sites and developed
new lipoatrophy there. She was then evaluated by aller-
gists at 2 different tertiary centers. One recommended
steroid therapy and the other recommended observation.
She chose clinical observation without steroid treatment.
In February 2014 lispro was used instead of glulisine
because the original lipoatrophy sites were not improv-
ing. In December 2014, 10 months after switching to
lispro and using abdominal sites only, no new lipoatro-
phy had appeared at infusion sites. Her latest A1C in
December 2014 was 7.2 %. Meanwhile the original lipoa-
trophy sites in the upper thighs, upper arms and abdomen
improved significantly (Fig. 3).
Information from the manufacturer
In their response to our request for information on lipoa-
trophy induced by detemir, aspart, detemir plus aspart the
manufacturer stated they did not have incidence data on
lipoatrophy associated with these insulin analogs [25].
Lipoatrophy induced by other insulin analogs
In the same literature search 17 cases of lispro, 2 cases
of lispro mixture, and 7 cases of glargine induced lipoa-
trophy were reported. No reported case of glulisine-
induced lipoatrophy was found. These cases are not
described in detail in this paper; but their details can be
obtained from the authors. Our new case of detemir plus
aspart induced lipoatrophy also developed lipoatrophy
when using glulisine, making it the first published
reported case of glulisine induced lipoatrophy.
Number of citations identified 
through searching 3 databases 
(n=644)
Number of citations after duplicates 
removed (n=520)
Pearling of full papers (13)Citations screened (n=22)
Papers (n=13) Abstracts (n=9) Pearling (n=0) 
Citations included in analysis (n=22)




Fig. 1 Flow chart showing the processes of identification, screening, elimination and inclusion in this review
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Table 1 Thirty-three lipoatrophy cases induced by detemir, aspart, detemir plus aspart, and NovoMix30
Year published
and country
Detemir Aspart Detemir plus aspart NovoMix30 (30 % aspart






65 yo Caucasian female with
late-onset TIDM started on
NovoMix 30. LA in both thighs
(onset not mentioned). When
switched to abdomen, new LA
developed. Did not resolve.
Szypowska et al.
Poland 2008 [6]
32 mo Caucasian boy with T1DM
using Asp in CSII. LA at infusion
sites in buttocks 10 months later.
Switched to Lispro and LA
reported at new infusion sites.
Del Olmo et al.
Spain 2008 [4]
30 yo female T1DM. Detemir
10 u hs. LA appear on thighs
“several” months after initiation.




Kesavadev J et al.
India 2008 [12]
55 yo Indian male with T2DM (?)
on CSII using Asp developed LA




7 yo girl with T1DM since age
1 yr. Started on CSII using Asp at
age 5 yrs. At age 7 yrs LA
developed at infusion sites on
buttocks and thighs.
Chang YT et al.
USA 2010 [14]
11 yo girl with T1DM on CSII
using Asp. Developed LA at
infusion sites after 1 yr. Previously
on MDI using Asp + glargine with
lipohypertrophy at injection sites.
Switched to lispro and applied




7 yo boy with T1DM on CSII using
Asp. Developed LA in infusion site
on buttocks within a year of starting
Asp. Switched to lispro and used a
different site. Applied pimecrolimus











Table 1 Thirty-three lipoatrophy cases induced by detemir, aspart, detemir plus aspart, and NovoMix30 (Continued)
Ninnikoski et al.
Finland 2010 [15]
15 yo boy with T1DM on CSII
using Asp. Developed LA in
infusion site on thighs within a
year of starting Asp. Switched to




10 yo girl with T1DM since age
5 years on CSII using Asp.
Developed LA in infusion sites on
thighs 4 yrs later. Switched to
lispro and changed site. Applied




4 yo Caucasian T1DM
NovoMix 30. LA 2-3 yrs after
insulin. LA in new injection
sites when site changed
Babiker et al.
UK 2011 [10]
5 yo Caucasian T1DM
NovoMix 30. LA 3 yrs after
insulin. LA in new injection
sites with Lispro 25/75
Babiker et al.
UK 2011 [10]
12 yo Caucasian T1DM Novorapid+
glargine. LA 3 yrs after insulin.




14 yo Caucasian T1DM
Novorapid+detemir. LA 3 yrs
after insulin. Detemir site only.
LA when detemir changed to
glargine.
George PS et al.
UK 2011 [16]
? yo woman with T1DM on CSII
using Asp. Developed LA at
infusion sites 2 years after initiation.
Previously on MDI using glargine
and Asp without LA.
Yazdanyar S et al.
Denmark 2011 [17]
17 yo girl with T1DM developed
lipoatrophy at aspart infusion
sites 1.5 years after starting CSII.
Previously used Biphasic Asp.
Switched to glulisine without
lipoatrophy.
Yazdanyar S et al.
Denmark 2011 [17]
8 yo boy with T1DM developed
LA as aspart infusion sites soon
after starting CSII. Previously used












Table 1 Thirty-three lipoatrophy cases induced by detemir, aspart, detemir plus aspart, and NovoMix30 (Continued)
Yazdanyar S et al.
Denmark 2011 [17]
7 yo girl with T1DM developed LA
at Aspart infusion sites 10 months
after starting CSII. Previously used
Asp and Biphasic Asp without LA.
Tavare AN et al.
UK 2011 [23]
53 yo Indian woman with T2DM
developed LA at Asp + Det
injection sites. Previously on
NovoMix 30 with itching and
erythema. Also developed LA
(onset not stated) and local
reaction to Lispro, Lispro 25/75,
glargine and Human Mixtard 30.
Peteiro-Gonzalez D et al.
Spain 2011 [18]
39 yo woman with T1DM on MDI-
glargine and Asp. LA at Asp sites
(thighs) 2 years after Asp therapy.
Also had primary hypothyroidism




42 yo man with T1DM since age
7 yrs. After CSII for 14 months, he
developed LA. Applied Na




7 yo female with T1DM CSII aspart.
LA (few months later) in buttocks
and thighs. Substituted with lispro
with no benefit.
Suththanantha J et al.
UK 2012 [21]
7 yo girl with T1DM developed LA




17 yo boy with T1DM developed
LA at Asp injection sites (on MDI).





54 yo female with T1DM.
Detemir in her thighs and
Aspart in her abdomen.
Lipoatrophy in her thighs.
Hypoglycemia improved




29 yo female with T1DM.
Detemir in her thighs and
Aspart in her abdomen.












Table 1 Thirty-three lipoatrophy cases induced by detemir, aspart, detemir plus aspart, and NovoMix30 (Continued)
Agha et al.
UK 2013 [11]
26 yo T1DM woman on detemir
and aspart developed LA at




32 yo T1DM woman on detemir
plus aspart developed LA at




64 yo female with T1DM.
Detemir in her thighs for
8 years. LA in thighs 2-3
years after starting it.
Breznik et al.
Slovenia 2013 [24]
62 yo T2DM woman on detemir
plus aspart developed LA 5.5 yrs
after starting insulin. Did not
resolve spontaneously. Biopsy
findings
Simeonovic M et al.
UK and Australia 2014 [22]
3 yo girl with T1DM developed
LA at Asp infusion site (buttock)
when on CSII (after 1-3 yrs).
Simeonovic M et al.
UK and Australia 2014 [22]
7 yo girl with T1DM developed
LA at Asp infusion site (abdomen)
when on CSII (1-3 yrs later).
Simeonovic M et al.
UK and Australia 2014 [22]
8 yo girl with T1DM developed
LA at Asp infusion site (thigh)
when on CSII (after 1-3 yrs).
Simeonovic M et al.
UK and Australia 2014 [22]
10 yo girl with T1DM developed
LA at Asp infusion site (abdomen)
when on CSII (after 1-3 yrs).
Saberi et al.
USA 2014 (our report)
41 yo T1DM woman developed
LA at injection sites on thighs,
upper arms and abdomen 14
months after starting aspart and
detemir MDI. When switched to
CSII (Omnipod) using aspart LA
developed within a year. When
switched to CSII using glulisine
LA developed after a year. When
switched to CSII using lispro no
new LA after 10 months. The
original LA began to fill in when
left alone.
41 yo T1DM woman developed
LA at injection sites on thighs,
upper arms and abdomen 14
months after starting aspart and
detemir MDI. When switched to
CSII (Omnipod) using aspart LA
developed within a year. When
switched to CSII using glulisine
LA developed after a year. When
switched to CSII using lispro no
new LA after 10 months. The













Based on our 2015 literature search of published reports,
our adult female patient with T1DM may be the 5th pub-
lished case of detemir plus aspart-induced lipoatrophy.
Aspart was launched in 2000 and detemir in 2006. The
first published report on detemir plus aspart-induced
lipoatrophy in 2011 was followed by 3 more cases in
2013. Among the previously reported 4 adult female pa-
tients with detemir plus aspart-induced lipoatrophy, 2
had T1DM [11] and 2 had T2DM [23, 24]. When both
detemir and aspart are injected in the same site, it is dif-
ficult to identify whether one or both of these insulin an-
alogs induced the lipoatrophy as either can cause it.
According to our patient, she injected aspart and dete-
mir in the same sites and could not determine which in-
sulin analog induced the lipoatrophy. When she was on
CSII using aspart and then glulisine she also developed
lipoatrophy at the infusion sites.
In the past, CSII was reported to treat lipoatrophy in-
duced by human insulin [26]. Today, lipoatrophy induced
by rapid-acting insulin analog is often associated with
CSII. Two recent surveys reported 83.3 % [27] and 87 %
[2] of patients with lipoatrophy induced by rapid-acting
insulin analogs use CSII. In our report 18 of the 21
(85.7 %) cases of aspart-induced lipoatrophy were associ-
ated with CSII and only 3 cases injected aspart. The infu-
sion may cause the lipoatrophy [22]. Together continuous
exposure to insulin and continuous mechanical irritation
by the infusion catheter may trigger events that lead to
lipoatrophy. Some patients did not develop lipoatrophy
when injecting aspart but did so when infusing aspart via
CSII [17, 22]. Others develop lipoatrophy with both injec-
tion and infusion implying the delivery method does not
matter. Our patient had aspart-induced lipoatrophy within
a year at the infusion sites when on CSII. She also devel-
oped lipoatrophy at the infusion sites when infusing gluli-
sine via CSII after a year. Ten months after infusing lispro
via CSII, she has not developed lipoatrophy at the infusion
sites. This may be because she has not infused lispro long
enough (one year or longer) as lipoatrophy can develop
from 4 weeks [9] to 5.5 years [24] after starting insulin. It
may also be because lispro does not induce lipoatrophy in
her. Although all 5 insulin analogs can induce lipoatrophy,
some patients have lipoatrophy induced by one but not
another [17].
Clinical presentation
Lipoatrophy is the loss of subcutaneous fat at insulin in-
jection/infusion sites as demonstrated by biopsy [18, 28]
and MRI [29]. In the past, 10 - 55 % of diabetic patients
injecting impure bovine or porcine insulin developed
lipoatrophy [1, 30]. With the availability of purer animal
and human insulin, the prevalence of lipoatrophy de-
creased to 0.2-1.4 % [30, 31]. With insulin analog injec-
tions/infusions, the prevalence of lipoatrophy had been
reported to be 2.5 % in a single center study [27] and
1.1 % in a multicenter survey [2].
There are no reported objective data for exact onset
of insulin-induced lipoatrophy. The reported first ob-
served onsets of insulin-induced lipoatrophy range
from 4 weeks to 2 years [9], 2–3 to 23 months [26]
to 6–24 months [1] after initiation of insulin therapy.
In our literature search the first observed onsets of
lipoatrophy range from 2 months to 5.5 years.
Lipoatrophy is more common in females in reported
cases of lipoatrophy. In our review, the gender of 29 pa-
tients was identified. Of these 22 (75.8 %) were females
and 7 males. Our patient is female. Why lipoatrophy is
more prevalent in women remains unclear. There may
be a reporting bias in this female gender predominance
as this data is based on case reports and not clinical
trials or MedWatch reports.
Lipoatrophy can overlap with other autoimmune dis-
eases [21, 32]. Female T1DM patients with lipoatrophy
Fig. 2 Lipoatrophy on thigh in November 2012
Fig. 3 Improved lipoatrophy on thigh in December 2014
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have a higher risk of developing Hashimoto’s thyroiditis
and celiac disease [32]. Autoimmune diseases affect 8 % of
the population and of these 78 % are females [33].
Whether lipoatrophy and autoimmune diseases in females
share a common etiology remains to be established. In
females with T1DM and insulin-induced lipoatrophy,
the physician should screen for other autoimmune dis-
ease(s). Our patient has Hashimoto’s thyroiditis with
hypothyroidism; she does not have celiac disease or pri-
mary adrenal insufficiency.
Many of the reported cases of lipoatrophy induced by
insulin analogs are in the pediatric population. Why this
is remains unanswered. In our review, 20 (60.6 %) of the
33 cases were in the pediatric age group: 1 with detemir,
17 with aspart, and 2 with NovoMix 30. Like the previ-
ous 4 reported cases of lipoatrophy induced by detemir
plus aspart injections, our case is an adult. Similarly, 4 of
the 5 cases of lipoatrophy induced by detemir were
adults. This probably reflects the age of patients using
detemir plus aspart and detemir alone. Lipoatrophy more
commonly occurs in T1DM partly because many cases
are in the pediatric age group and possibly due to a poten-
tial immune-mediated inflammation causing lipoatrophy
in patients with autoimmune type 1 diabetes. In our re-
port, 31 of the 33 patients had T1DM and 2 had T2DM.
Our patient has T1DM.
Lipohypertrophy sites from insulin injection can lead
to impaired insulin absorption [34, 35]. To the best of
our knowledge there are no published insulin absorption
studies done in insulin analog-induced lipoatrophy sites.
But, it is reasonable to expect variable insulin absorption
in lipoatrophy sites with loss of adipose tissue, making gly-
cemic control challenging. Some patients improved their
glycemic control when insulin injection site is changed
from the lipohypertrophy to an unaffected site [36]. One
patient with lipoatrophy had improved glycemic control
when the injection site was changed [11]. Another pa-
tient improved his glycemic control when given intra-
peritoneal insulin suggesting that the lipoatrophy may
have been causing poor insulin absorption [37]. Changing
the injection or cannula site in our patient did not signifi-
cantly affect her glycemic control. Clinically, insulin-
induced lipoatrophy can be cosmetically distressing and
disfiguring to the patient. For these reasons, the clinician
should inspect the insulin injection/infusion sites regu-
larly to identify lipodystrophy (lipohypertrophy and/or
lipoatrophy), especially in patients with erratic glycemic
control, so measures to manage the problem and prevent
the development of further areas of lipoatrophy can be
implemented.
As all these are reported cases, the number of cases
of lipoatrophy induced by each insulin analog cannot be
compared. However, all insulin analogs can induce
lipoatrophy.
Etiology
Many possible etiologies have been considered for insulin-
induced lipoatrophy. These include cresol preservative in
insulin, alcohol used for sterilization of syringes and nee-
dles, injury to the fat cells, glycolytic ferments in the insu-
lin, possible nerve injury [38], mechanical trauma from
repeat injections, and cryotrauma from cold insulin [10].
Immune etiologies have also been suggested - immune re-
action to insulin [39, 40] and immune complex mediated
inflammation [26]. Lipoatrophic lesions occurred in in-
dividuals using animal insulins who have high levels of
circulating anti-insulin antibodies and the edges of lipoa-
trophy lesions were characterized by deposition of im-
munologic proteins within dermal vessel [39]. Although
this had been questioned, a strong relationship between
lipoatrophy and insulin antibodies was recently reported
in adults with T2DM on recombinant human insulin or
insulin analogs [41]. The immune-complex mediated in-
flammatory response involves local macrophage release of
tumor necrosis factor α causing adipocyte dedifferenti-
ation [26, 42] in patients using both animal and recombin-
ant human insulin. Increased numbers of degranulating
mast cells that stain positively for tryptase and chymase
antibodies have also been seen in skin biopsies of patients
with lipoatrophic sites of insulin analogs [43]. Hist-
ology has shown small adipocyte lobules with hyperplastic
capillaries, loss of adipose tissue, areas of membranous
lipodystrophy usually lined by an acellular homogeneous
eosinophilic material and a focal lymphoid cell infiltration
abutting hypodermis blood vessels [26, 44] in patients
using both animal and human insulins. Although several
studies have demonstrated a possible immune basis to the
etiology of lipoatrophy, there are others which do not.
Jermendy et al. reported absence of inflammatory cells and
no local immune mechanisms in the biopsy specimen [44].
Milan et al. suggested that adipose tissue metabolic
changes play a role in lipoatrophy as they did not identify
any inflammatory cells in the skin biopsy specimens of
their three T1DM patients with lipoatrophy by insulin ana-
logs [28]. This study demonstrated a decrease in fat cell
volume with adipocytes losing their lipid content leading
to the hypothesis that adipocytes chronically exposed to
high local insulin levels could develop insulin resistance
resulting in an increase in the lipolytic process causing
lipoatrophy. A significant down-regulation of leptin ex-
pression along with an increase in free fatty acid was also
seen which was thought to result in the recruitment of fat
cell precursors [28].
Treatment
A change in insulin formulation, avoiding injections in
the lipoatrophy sites (our patient noted this when the
Omnipod was used near the sites), and changing the
insulin needle daily have helped resolve lipoatrophy in
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some patients [3]. There are also case reports of adding
glucocorticoid therapy such as dexamethasone or beta-
methasone to the insulin analog [20, 45]; but this can
cause blood glucose fluctuations if the betamethasone/
insulin analog solution becomes inhomogenous resulting
in erratic insulin administration [20]. Administering low-
dose oral glucocorticoid such as prednisone 5–10 mg
daily [46, 47] has also been used to improve lipoatrophy.
Corticosteroids are able to induce differentiation of adi-
pocytes and have immune-modulating properties [45].
However, addition of glucocorticoid therapy can result in
worsening glycemic control and increased insulin re-
quirements [20]. Our patient declined the recommen-
dation of using steroids. Yet, with time and not using
the lipoatrophy sites, the original lipoatrophy began
to improve (Fig. 3).
Changing the mode of insulin delivery, such as using
CSII, can potentially improve lipoatrophy in patients
using human insulin injections [48]. However, in our
literature review, 18 of the 21 cases of lipoatrophy in-
duced by aspart were associated with CSII which has
been hypothesized to contribute to the development of
lipoatrophy [22]. Why the largest increase in aspart-
induced lipoatrophy occurred in those on CSII remains
unclear. There may be a reporting bias in this group as
this data is based on case reports and not clinical trials
and Medwatch reports. Our patient developed lipoatro-
phy when on CSII using aspart and glulisine.
In 2 small studies topical 4 % sodium cromolyn in pet-
rolatum solvent was partially effective therapy for early
lipoatrophy areas and prevention of the development of
new such areas [43, 49]. Our literature review described 2
other cases of lipoatrophy induced by aspart which im-
proved with sodium cromolyn therapy [15, 19]. Cromolyn
stabilizes mast cells that are tryptase-positive/chymase-
positive and prevents the release of histamine in the pres-
ence of antigen-IgE antibody reactions [43].
Finally, 2 case reports described treatment of insulin-
induced lipoatrophy. The first one is treating lipoatrophy
successfully with an insulin jet –injector [50]. In an
extremely refractory case Noud et al. used intraperito-
neal insulin delivered by Diaport [37]. Inhaled insulin
can potentially be used in patients with lipoatrophy in-
duced by injected insulin. Lipoatrophy was not described
as an adverse event in the Afreeza® product monograph
[51]. We are aware that in Afreeza® trials high anti-
insulin antibodies titers were documented. To the best
of our knowledge no case of insulin lipoatrophy has
been described in the Afreeza® clinical trials. Possible
explanations for this include [a] without repeated injec-
tions of insulin no atrophy occurs despite the high insu-
lin antibodies tiers; [b] an uncommon complication like
insulin induced lipoatrophy may not appear in the lim-
ited number of patients who have used Afreeza thus far;
and [c] the association of high insulin antibodies titers
and injected insulin lipoatrophy does not imply a cause-
effect association.
Conclusion
Our case may be the 5th case of detemir plus aspart in-
duced lipoatrophy and possibly the first published case
report of glulisine induced lipoatrophy. In prescribing in-
formation for Apidra [7] lipoatrophy was mentioned.
There are 30 new published cases of aspart, detemir, dete-
mir plus aspart and NovoMix induced lipoatrophy since
2009. These represent only a percentage of the cases of
lipoatrophy induced by these insulin analogs. The ISPAD
survey [2], the single center study [27] and the recent
Rosenbloom recidivus [38] mentioned many cases (some
due to these insulin analogs) which have not been pub-
lished. To better understand insulin analog-induced lipoa-
trophy, more research on the prevalence of this cutaneous
complication of insulin therapy, its etiology, pathogenesis
and management need to be conducted. It is unrealistic to
expect every case of insulin analog induced lipoatrophy to
be published. But, sharing of data on reported, but not
published, cases can be helpful.
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